You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GEP-NEN

Showing 1 - 25 of 105
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Financial Toxicity and Patient-Reported Outcomes in GEP-NEN

Recruiting
  • Neuroendocrine Tumors
    • Milan, Italy
      IRCCS Ospedale San Raffaele
    Apr 16, 2022

    Neuroendocrine Tumors Trial in Beijing (177Lu-Dotatate PRRT)

    Unknown status
    • Neuroendocrine Tumors
    • 177Lu-Dotatate PRRT
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Feb 5, 2020

    GEP-NET, Neuroendocrine Tumors, Neuroendocrine Carcinoma Trial in Copenhagen (18F-FDG, 64Cu-Dotatate)

    Enrolling by invitation
    • GEP-NET
    • +3 more
    • Copenhagen, Denmark
      Rigshospitalet
    Jan 24, 2023

    Models in Neuroendocrine Neoplasm

    Recruiting
    • Neuroendocrine Neoplasm
    • Biopsy, open or laparoscopic surgery
    • Shanghai, Shanghai, China
      Department of Pancreatic Surgery, Fudan University Shanghai Canc
    Sep 19, 2021

    Neuroendocrine Tumors Trial in Seoul (Lanreotide autogel)

    Recruiting
    • Neuroendocrine Tumors
    • Lanreotide autogel
    • Seoul, Korea, Republic of
      Changhoon Yoo
    Jul 18, 2022

    Cancer Trial in Heidelberg, Mainz (combination of Avelumab and Cabozantinib)

    Recruiting
    • Cancer
    • combination of Avelumab and Cabozantinib
    • Heidelberg, Germany
    • +1 more
    Mar 31, 2022

    Neuroendocrine Tumors Trial in Sweden (177Lu-DOTATOC, Capecitabine)

    Not yet recruiting
    • Neuroendocrine Tumors
    • Göteborg, Sweden
    • +3 more
    May 19, 2022

    Neuroendocrine Tumors, Frailty, Chemo Effect Trial in Milan (Temozolomide capsule)

    Recruiting
    • Neuroendocrine Tumors
    • +2 more
    • Temozolomide capsule
    • Milan, Italy
      European Institute of Oncology, IEO, IRCCS
    Sep 21, 2022

    Breast Cancer, Neuroendocrine Tumors, Neuroendocrine Carcinoma Trial in Copenhagen (18F-FDG, Injection of hyperpolarized

    Enrolling by invitation
    • Breast Cancer
    • +3 more
    • Copenhagen, Denmark
      Rigshospitalet
    Jan 18, 2023

    Lung Neuroendocrine Tumor, GEP Neuroendocrine Tumor Trial in Naples (Cabozantinib and Temozolomide)

    Recruiting
    • Lung Neuroendocrine Neoplasm
    • GEP Neuroendocrine Tumor
    • Cabozantinib and Temozolomide
    • Naples, Campania, Italy
      National Cancer Institute of Naples
    Oct 12, 2021

    Early Treatment Response in NEN (REBORN)

    Recruiting
    • Neuroendocrine Tumors
    • +4 more
    • Somatostatin analog; chemotherapy
    • Rome, Italy
      Andrea M Isidori
    Dec 2, 2020

    Neuroendocrine Tumors Trial in Innsbruck, Kraków, Ljubljana ([99mTc]Tc-TECANT1)

    Recruiting
    • Neuroendocrine Tumors
    • Innsbruck, Austria
    • +2 more
    May 12, 2023

    Chromogranin A as Blood Marker in Cancer Patients

    Completed
    • Gastric Neoplasms
    • +3 more
    • BRAHMS CgA II KRYPTOR
    • Palo Alto, California
    • +3 more
    Dec 19, 2022

    Neuroendocrine Neoplasia's (NENs), Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) Trial in Basel (161Tb-DOTA-LM3,

    Not yet recruiting
    • Neuroendocrine Neoplasia's (NENs)
    • Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
    • Basel, Switzerland
      Division of Nuclear Medicine, University Hospital Basel
    Apr 27, 2022

    Cancer Trial in Germany (Avelumab)

    Completed
    • Cancer
    • Halle (Saale), Germany
    • +3 more
    Feb 24, 2022

    Advanced NSCLC Trial in Worldwide (Pembrolizumab, Favezelimab, Lenvatinib)

    Active, not recruiting
    • Advanced Non-Small Cell Lung Cancer
    • Pembrolizumab
    • +3 more
    • Tempe, Arizona
    • +80 more
    Aug 23, 2022

    Gastroenteropancreatic Neuroendocrine Tumours

    Recruiting
    • Gastroenteropancreatic Neuroendocrine Tumor
    • 68Ga-DOTATOC PET as a part of their clinical diagnostic work-up will be included
    • Milano, Italy
      Irccs San Raffaele
    Nov 24, 2023

    Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine

    Not yet recruiting
    • Digestive System Neuroendocrine Tumor G1
    • +5 more
    • Tumor Debulking
    • +5 more
    • Nashville, Tennessee
      Vanderbilt University/Ingram Cancer Center
    Aug 23, 2023

    Neuroendocrine Carcinomas Trial in France (Folfiri-bevacizumab, Folfiri)

    Recruiting
    • Neuroendocrine Carcinomas
    • Amiens, France
    • +26 more
    Jan 26, 2022

    Neuroendocrine Tumors, Neuroendocrine Carcinoma Trial in Germany (Cabozantinib)

    Recruiting
    • Neuroendocrine Tumors
    • Neuroendocrine Carcinoma
    • Göttingen, Lower Saxony, Germany
    • +5 more
    Jun 27, 2022

    Acromegaly, GEP-NET Trial in Worldwide (Debio 4126, Sandostatin LAR, Somatuline ATG)

    Recruiting
    • Acromegaly
    • GEP-NET
    • Debio 4126
    • +2 more
    • Copenaghen, Denmark
    • +34 more
    Jan 27, 2023

    Neuroendocrine Tumors, Peptide Receptor Radionuclide Therapy Trial in Rotterdam (olaparib)

    Recruiting
    • Neuroendocrine Tumors
    • Peptide Receptor Radionuclide Therapy
    • Rotterdam, South Holland, Netherlands
      Erasmus MC
    May 19, 2023

    Gastroenteropancreatic Neuroendocrine Tumors Trial in Marseille ([68Ga]-DOTANOC PET/CT)

    Completed
    • Gastroenteropancreatic Neuroendocrine Tumors
    • [68Ga]-DOTANOC PET/CT
    • Marseille, France
      AP-HM
    Oct 12, 2022

    Donor Derived Cell Free DNA and Histopathology in Kidney

    Not yet recruiting
    • Transplant;Failure,Kidney
    • +2 more
      • (no location specified)
      Apr 11, 2023

      Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma Trial in Worldwide (Lutetium [177Lu]

      Recruiting
      • Gastroenteropancreatic Neuroendocrine Tumors
      • +2 more
      • Lutetium [177Lu] oxodotreotide/dotatate
      • Iowa City, Iowa
      • +16 more
      Apr 6, 2022